trending Market Intelligence /marketintelligence/en/news-insights/trending/o8-u8bmbdb7oqonbhqqfiw2 content esgSubNav
In This List

Catalyst's autoimmune disorder drug secures US FDA priority review

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Catalyst's autoimmune disorder drug secures US FDA priority review

Catalyst Pharmaceuticals Inc. said the U.S. Food and Drug Administration granted priority review to its application for Firdapse as a treatment of Lambert-Eaton myasthenic syndrome, or LEMS.

LEMS is a rare autoimmune disorder characterized by muscle weakness of the limbs.

The Coral Gables, Fla.-based biotechnology company said the FDA will make a decision on the application Nov. 28.

The submission is supported by the results of two phase 3 studies.